Locally Advanced Cervical Cancer Clinical Trial
Official title:
Non-randomized Concurrent Controlled Trial of Surgery Staging or Image Staging of Locally Advanced Cervical Cancer
The study is a domestic multicenter, prospective, non-randomized controlled concurrent trial. It will be assessed whether surgery staging on locally advanced cervical cancer is superior to image staging for improving progression-free survival and overall survival.
All eligible patients will be divided into the following two treatment groups nonrandomly. Image staging group: standard chemoradiation (Pelvic EBRT/Extended-field EBRT + concurrent platinum-containing chemotherapy+brachytherapy). Surgery staging group: open/minimally invasive para-aortic lymph node dissection followed by concurrent chemoradiation. (Level of lymph node dissection: At least the inferior mesenteric artery. Chemoradiation will be conducted within 28 days postoperatively.) ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03225443 -
Observation and Evaluation of Short-term Curative Effect of Local Advanced Cervical Cancer Treated With Particle Radiotherapy Versus Neoadjuvant Chemotherapy
|
N/A | |
Recruiting |
NCT06079671 -
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
|
Phase 3 | |
Completed |
NCT05059119 -
Rectovaginal Fistula in Post-Radiotherapy Advanced Cervical Cancer Patients
|
||
Recruiting |
NCT06055738 -
Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC
|
Phase 2 | |
Recruiting |
NCT06156514 -
Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer
|
Phase 3 | |
Completed |
NCT03298893 -
Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01514955 -
An Initial Feasibility Study to Integrate MRI Based Brachytherapy and CT/MR Fused INRT in Treatment of Advance Cervical Cancer
|
Phase 1 | |
Recruiting |
NCT05950087 -
Study on the Relationship Between Plasma MRD and cfDNA HPV and the Efficacy and Prognosis of Locally Advanced Cervical Cancer After Concurrent Chemoradiotherapy
|
||
Recruiting |
NCT04884906 -
Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05799469 -
Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical Cancer
|
Phase 2 | |
Recruiting |
NCT05311566 -
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
|
Phase 2 | |
Terminated |
NCT02045433 -
Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer
|
Phase 2 | |
Recruiting |
NCT06237257 -
A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06288360 -
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
|
Phase 2 | |
Not yet recruiting |
NCT06288373 -
Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC
|
Phase 2/Phase 3 | |
Recruiting |
NCT06068387 -
A Prospective Study on the Prediction Model of Para-aortic Lymph Node Metastasis
|
N/A | |
Recruiting |
NCT03963882 -
NAC Followed by RH for the Treatment of LACC
|
Phase 2 | |
Recruiting |
NCT01938105 -
Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01793701 -
Intensity-modulated Radiotherapy for Locally Advanced Cervical Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01230996 -
Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer
|
Phase 1/Phase 2 |